Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2020-01-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
首次公开发行股票并在科创板上市发行安排及初步询价公告
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding the initial public offering (IPO) of 百奥泰生物制药股份有限公司 on the Shanghai Stock Exchange's STAR Market (科创板). It includes extensive information about the issuance arrangement, preliminary inquiry, pricing, investor qualifications, subscription procedures, allotment, and related regulatory compliance. The text references regulatory approvals from the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange rules, and it outlines the process for the IPO including strategic placement, offline and online issuance, pricing, and subscription timelines. The document is not a financial report, earnings release, or management discussion but rather a comprehensive issuance and financing update related to the company's capital raising event. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement but a substantive update on the capital issuance process.
2020-01-22 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.